Clinical Trial Update: Clinical Trial of Efficacy and Safety of Prospekta in the Treatment of Attention Deficit/Hyperactivity Disorder in Children [Phase 3]

View source ↗

Summary

Phase 3 trial evaluating Prospekta in children with attention-deficit/hyperactivity disorder has completed. Results were posted on 2024-08-01.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Attention Deficit Hyperactivity Disorder

Drugs mentioned

• Prospekta

Snippet

Sponsor: Materia Medica Holding | Conditions: Attention Deficit Hyperactivity Disorder | Phase 3 | Status: COMPLETED | Results posted: 2024-08-01